Breast
An observational study of circulating tumor DNA in triple negative breast cancers with residual disease after standard neoadjuvant treatment.
Volunteers
Health Professionals
What is the purpose of this trial?
Estimate the ctDNA positivity rate in triple negative breast cancer (TNBC) patients with residual disease after completion of neoadjuvant chemotherapy and surgery.
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.
Principal Investigator
Sub-Investigators
- Last Updated08/07/2024
- Study HIC#2000033096